Form 4: Biogen Executive Sells Shares Under Pre-Arranged Trading Plan

Biogen's Head of Global Product Strategy, Rachid Izzar, reported the sale of 2,223 shares of common stock for $135 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Rachid Izzar, Biogen Inc.'s Head of Global Product Strategy, reported a transaction involving the disposition of common stock.
• The transaction occurred on July 8, 2025, and involved the sale of 2,223 shares of Biogen common stock.
• Each share was sold at a price of $135.
• Following this sale, Rachid Izzar beneficially owns 6,330 shares of Biogen common stock.
• The transaction was conducted pursuant to a Rule 10b5-1(c) contract, instruction, or written plan, indicating a pre-arranged sale.

Sentiment

Score: 5

Explanation: The sale of shares by an executive, particularly when executed under a Rule 10b5-1 plan, is generally considered a neutral event as it represents a pre-arranged personal financial management decision rather than a direct signal about the company's performance or outlook.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

NA

Comparison to Industry Standards

• NA

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders may view the sale as a neutral event given it was executed under a Rule 10b5-1 plan, which indicates a pre-scheduled transaction rather than a reaction to new information.

Next Steps

• NA

Key Dates

Keywords

Biogen, BIIB, Insider Trading, Form 4, Stock Sale, Executive Compensation, Rule 10b5-1